Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

BioPharma Dive

The partners said the shot produced clinically meaningful efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.

Regulatory Infectious Disease Read full story